Eli Lilly said on Wednesday patients on obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's ...

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...

A Center for Eye Research Australia study has linked low levels of oxygen in the blood overnight—a common sign of obstructive ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in ...

A staggering 70% of adults report experiencing insufficient sleep at least once a month, according to the US Centers for Disease Control and Prevention (CDC). (1) Despite this, 80% to 90% of ...

Wegovy was approved in the US as a treatment for heart disease in March, while Zepbound is expected to be given the green ...

Understanding Obesity and Sustainable Eating Habits to Combat Obesity - Dietitian Sarita Rai, M. sc, CDE Obesity is a type of ...

A rival drug company is celebrating results claiming its drug helps patients lose more weight than Novo Nordisk’s Wegovy. Eli ...

Nocturnal enuresis is more common in children with obstructive sleep apnea (OSA), according to a study published online Sept.

There are bidirectional associations for sleep disorders with chronic kidney disease (CKD), according to a study.

Sleep Apnea Devices MarketThe global Sleep Apnea Devices Market is projected to experience robust growth, registering a ...

People with high blood pressure who also lack sleep may be at increased risk of reduced cognitive performance and greater brain injury, Monash University research has found.